Akebia Therapeutics
AKBA
150 hedge funds and large institutions have $334M invested in Akebia Therapeutics in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 44 reducing their positions, and 21 closing their positions.
4,023% more call options, than puts
Call options by funds: $19.3M | Put options by funds: $468K
0% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 44
1% less funds holding
Funds holding: 151 → 150 (-1)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
2.05% less ownership
Funds ownership: 73.76% → 71.7% (-2.1%)
21% less capital invested
Capital invested by funds: $421M → $334M (-$86.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$1.62M |
| 2 |
BlackRock
New York
|
+$1.51M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.27M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.21M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.23M |
| 2 |
Man Group
London,
United Kingdom
|
-$2.44M |
| 3 |
OWIM
Old West Investment Management
Los Angeles,
California
|
-$935K |
| 4 |
Morgan Stanley
New York
|
-$809K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$785K |
AKBA Hedge Fund Activity: Q3 2019 in Review
150 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2019, worth a combined $334M — down 21% from $421M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AKBA and 20 opened new positions — a net loss of 1 holder — while 44 trimmed existing stakes and 44 added.
The largest buyer was Sofinnova Investments, adding an estimated $1.62M. The largest seller was State Street, cutting an estimated $9.23M.
- 150 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2019, down from 151 in Q2 2019.
- Funds reported $334M of Akebia Therapeutics stock for Q3 2019, down 21% quarter-over-quarter.
- 20 funds opened new Akebia Therapeutics positions in Q3 2019 and 21 closed out, a net change of -1 holder.
- The largest Akebia Therapeutics buyer in Q3 2019 was Sofinnova Investments, an estimated $1.62M added.
- The largest Akebia Therapeutics seller in Q3 2019 was State Street, an estimated $9.23M sold.
Based on aggregated 13F filings for Q3 2019.